A Takeda spinout builds case for its Parkinson’s drug
Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Drug target could block brain inflammation linked to Alzheimer’s and Parkinson’s sciencedaily.com
- ‘Absolutely staggering’: Results from experimental drug trial to prevent Parkinson’s disease theage.com.au
- ‘Absolutely staggering’: Results from experimental drug trial to prevent Parkinson’s disease smh.com.au